Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer
Authors:
- 5 May 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 187 (3) , 625-633
Abstract
Purpose The heterogeneity of triple-negative breast cancer (TNBC) confers variable response to chemotherapy that results in poor outcome and relapse. Due to lack of targeted therapy, there is a need to provide molecular classification of TNBC and identify probable therapeutic targets. Methods We classified TNBC into surrogate molecular subtypes by immunohistochemistry and evaluated hotspot mutations (N = 80) in PIK3CA (exon 4, 9, and 20) and AKT1 (exon 2) in TNBC subtypes by Sanger sequencing. Results TNBCs were classified into Basal-like 1(BL1) (n = 20, 25%), Mesenchymal (n = 19, 23.75%), Luminal Androgen (LAR) (n = 12, 15%), Basal+Mesenchymal (Mixed type) (n = 10, 12.5%), and unclassified subtype (n = 19, 23.75%). PIK3CA mutations were observed in 16.25% (13/80) TNBC cases. PIK3CA mutations were more frequent in exon 20 (8.7%) than in exon 9 (5%) and exon 4 (2.5%). PIK3CA mutations were frequent in LAR subtype (33.3%) followed by unclassified type (31.5%), Mesenchymal (10.5%), and BL1 (5%) subtypes. Two hotspot mutations were found in AKT1 (T21I, E17K) in mixed and unclassified subtype. Conclusions This study highlights the heterogeneity within TNBCs. Higher frequencies of PIK3CA mutations were noted in LAR subtypes and unclassified type, comparable to their incidence reported in literature in ER-positive tumors. The mutation status can be used as potential biomarker for PI3K inhibitors in TNBC subgroups.Keywords
Funding Information
- Anusandhan National Research Foundation ((EMR/2016/007000))
This publication has 32 references indexed in Scilit:
- Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate MarkersClinical Breast Cancer, 2018
- Inhibition of the PI3K/AKT/mTOR Pathway in Solid TumorsJournal of Clinical Oncology, 2016
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy SelectionPLOS ONE, 2016
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerClinical Cancer Research, 2015
- Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differencesOncotarget, 2014
- Phosphatidylinositol 3-kinase (PI3KCA) Oncogene Mutation Analysis and Gene Expression Profiling in Primary Breast Cancer PatientsAsian Pacific Journal of Cancer Prevention, 2013
- Deregulation of the Akt Pathway in Human CancerCurrent Cancer Drug Targets, 2008
- Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patientsCancer, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast CancerJournal of Clinical Oncology, 2006